These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 22050695)

  • 1. Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen.
    Chini M; Tsoupras AB; Mangafas N; Tsogas N; Papakonstantinou VD; Fragopoulou E; Antonopoulou S; Gargalianos P; Demopoulos CA; Lazanas MC
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):766-75. PubMed ID: 22050695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naive HIV-infected patients: ii) study of the abacavir/lamivudine/efavirenz HAART regimen.
    Chini M; Tsoupras AB; Mangafas N; Tsogas N; Papakonstantinou VD; Fragopoulou E; Antonopoulou S; Gargalianos P; Demopoulos CA; Lazanas MC
    Int J Immunopathol Pharmacol; 2012; 25(1):247-58. PubMed ID: 22507337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection?
    Tsoupras AB; Chini M; Tsogas N; Fragopoulou E; Nomikos T; Lioni A; Mangafas N; Demopoulos CA; Antonopoulou S; Lazanas MC
    AIDS Res Hum Retroviruses; 2008 Aug; 24(8):1079-86. PubMed ID: 18620493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-activating factor and its basic metabolic enzymes in blood of naive HIV-infected patients.
    Tsoupras AB; Chini M; Mangafas N; Tsogas N; Stamatakis G; Tsantila N; Fragopoulou E; Antonopoulou S; Gargalianos P; Demopoulos CA; Lazanas MC
    Angiology; 2012 Jul; 63(5):343-52. PubMed ID: 21948973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure.
    Detopoulou P; Nomikos T; Fragopoulou E; Antonopoulou S; Kotroyiannis I; Vassiliadou C; Panagiotakos DB; Chrysohoou C; Pitsavos C; Stefanadis C
    Clin Biochem; 2009 Jan; 42(1-2):44-9. PubMed ID: 18955040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAF and its metabolic enzymes in healthy volunteers: interrelations and correlations with basic characteristics.
    Detopoulou P; Nomikos T; Fragopoulou E; Stamatakis G; Panagiotakos DB; Antonopoulou S
    Prostaglandins Other Lipid Mediat; 2012 Jan; 97(1-2):43-9. PubMed ID: 22079887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
    Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
    J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline and 6-Week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers--a pilot study.
    Detopoulou P; Fragopoulou E; Nomikos T; Antonopoulou S; Kotroyiannis I; Vassiliadou C; Panagiotakos DB; Chrysohoou C; Pitsavos C; Stefanadis C
    Angiology; 2013 Oct; 64(7):522-8. PubMed ID: 23000600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
    Elion R; Cohen C; Gathe J; Shalit P; Hawkins T; Liu HC; Mathias AA; Chuck SL; Kearney BP; Warren DR;
    AIDS; 2011 Sep; 25(15):1881-6. PubMed ID: 21811136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of adherence and efficiency when replacing an antiretroviral therapy with efavirenz-emtricitabine-tenofovir in a single daily dose].
    García-Ramos SE; Santolaya Perrín MR; Fernández-Pacheco García-Valdecasas M
    Farm Hosp; 2012; 36(5):315-20. PubMed ID: 22858089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
    Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.
    Papakonstantinou VD; Chini M; Mangafas N; Stamatakis GM; Tsogas N; Tsoupras AB; Psarra K; Fragopoulou E; Antonopoulou S; Gargalianos P; Demopoulos CA; Lazanas MC
    Lipids Health Dis; 2014 May; 13():90. PubMed ID: 24884881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.